FDA Sends Back Filing For Pfizer's Tafamidis, Acquired in FoldRx Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Two months after Pfizer files an NDA for the orphan drug, the agency issues a Refusal To File Letter requesting more information.